TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02283515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
Study: NCT01121692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Intervention
Description: The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's CoOp
Description: The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's CoOp and Men's Intervention
Description: The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
Study: NCT04681482

Intervention type: DRUG
Intervention: Apixaban
Description: Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation.
Study: NCT03608774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.
Study: NCT03125434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EOS full-spine, MRI, gait analysis
Description: full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
Study: NCT02609334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRD007
Description: One single dose given 3 hours prior to Mannitol challenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRD007
Description: One single dose given 3 hours prior to Mannitol challenge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single dose given 3 hours prior to Mannitol challenge
Study: NCT03766854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine U100
Description: Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine U100
Description: Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks
Study: NCT04305795

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 200 mg Pembrolizumab
Description: every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 350 mg Cemiplimab
Description: every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 350 mg Cemiplimab
Description: every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ASP-1929
Description: ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ASP-1929
Description: ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ASP-1929
Description: ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months.
Study: NCT00699556

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 21mg transdermal nicotine patch (Nicoderm CQ)
Description: 21mg transdermal nicotine patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21mg transdermal nicotine patch (Nicoderm CQ)
Description: 21mg transdermal nicotine patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg nicotine nasal spray
Description: two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
Study: NCT03022292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Ophthalmic
Description: IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optovue angiovue
Description: FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
Study: NCT02895958

Intervention type: DRUG
Group type: OTHER
Intervention: Zepatier
Description: Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
Study: NCT03979638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Four escalating doses of BLU-5937 administered BID over the course of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for BLU-5937
Study: NCT02661360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swaddling Intervention for Preterm Infants
Description: Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swaddling Intervention for Preterm Infants
Description: Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unswaddled Control
Description: Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unswaddled Control
Description: Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
Study: NCT05810090

Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Description: patient who received a TKA in our hospital
Study: NCT00628602

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BION
Description: 30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION
Description: 30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group).
Study: NCT03873870

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga -DOTATATE PET scans
Description: PET scan using 68Ga-DOTATATE contrast
Study: NCT03996798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disability Case Manager
Description: The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
Study: NCT02003885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: increment of desflurane
Description: After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.~After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.~Reduction of BP is managed by the increment of phenylephrine infusion
Study: NCT01674868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: 20 mg daily for 90 days starting day 5-10 after stroke.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subjects will take one pill po daily for 90 days.
Study: NCT02120573

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture and human model
Description: workshop to teach CPR with lecture and human models

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture and human model
Description: workshop to teach CPR with lecture and human models

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture and human model
Description: workshop to teach CPR with lecture and human models

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Educational Film
Description: workshops using film review about CPR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Educational Film
Description: workshops using film review about CPR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Educational Film
Description: workshops using film review about CPR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture, human model as well as Educational Film
Description: using educational films and human model and lecture for training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture, human model as well as Educational Film
Description: using educational films and human model and lecture for training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture, human model as well as Educational Film
Description: using educational films and human model and lecture for training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture, human model, Educational Film as well as reference book
Description: training volunteers with lecture, films, and human models and giving them reference book for referral

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture, human model, Educational Film as well as reference book
Description: training volunteers with lecture, films, and human models and giving them reference book for referral

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture, human model, Educational Film as well as reference book
Description: training volunteers with lecture, films, and human models and giving them reference book for referral
Study: NCT01044095

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist® live, attenuated, intranasal seasonal influenza vaccine
Description: FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist® live, attenuated, intranasal seasonal influenza vaccine
Description: FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist® live, attenuated, intranasal seasonal influenza vaccine
Description: FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® inactivated influenza virus vaccine
Description: Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® inactivated influenza virus vaccine
Description: Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® inactivated influenza virus vaccine
Description: Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
Study: NCT00209079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gleevec, Taxotere
Description: Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
Study: NCT04617691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as IV solution derived from FVP or PFS-U.
Study: NCT00625027

Intervention type: OTHER
Intervention: Survey and Chart Review
Description: After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
Study: NCT02735772

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transobturator approach for paravaginal repair
Description: using TOT needle to apply suturs to white line
Study: NCT03851302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Remote Ischemic Conditioning
Description: The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning
Description: The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric hand exercise
Description: Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric hand exercise
Description: Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
Study: NCT02800096

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gambling Internet intervention
Description: The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Internet intervention
Description: The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoodGYM
Description: Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
Study: NCT01157819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% Ciprofloxacin Ear Drops
Description: 4 gtt b.i.d. for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FoamOtic Cipro
Description: 0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
Study: NCT01224171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: Vedolizumab for intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion
Study: NCT03809702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
Study: NCT02264444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cholecystectomy visualization
Description: Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
Study: NCT03503188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Littmann ®
Description: electronic stethoscope
Study: NCT02502994

Intervention type: DRUG
Group type: OTHER
Intervention: GEN0101
Study: NCT03448458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT (Computed Tomography)
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04429269

Intervention type: DIAGNOSTIC_TEST
Intervention: mammography and ultrasound screening
Description: Patients screened by both mammography and ultrasound.